DRUG

Bright Minds Biosciences Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↓ 1/10
  • Value↑ 6/10
Bright Minds Biosciences sales and earnings growth
DRUG Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -1029.17%
  • FCF Y/Y↓ -415.88%
Bright Minds Biosciences gross and profit margin trends
DRUG Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -4468.16%
Bright Minds Biosciences net debt vs free cash flow
DRUG Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Bright Minds Biosciences stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗